Valuation: COMPASS Pathways plc

Market Cap 1.83B 1.59B 1.49B 1.36B 2.57B 174B 2.6B 17.38B 6.82B 87.03B 6.87B 6.72B 290B P/E 2026 *
-12.2x
P/E 2027 * -8.04x
Enterprise Value 1.4B 1.22B 1.14B 1.04B 1.97B 134B 1.99B 13.32B 5.23B 66.7B 5.26B 5.15B 222B EV / Sales 2026 *
-
EV / Sales 2027 * 21.4x
Free-Float
25.07%
Yield 2026 *
-
Yield 2027 * -
1 day-0.22%
1 week+17.11%
Current month+19.38%
1 month+5.53%
3 months+38.83%
6 months+118.90%
Current year+96.38%
1 week 11.02
Extreme 11.0208
13.77
1 month 10.59
Extreme 10.59
14.6
Current year 4.88
Extreme 4.88
15.4
1 year 3.97
Extreme 3.97
15.4
3 years 2.25
Extreme 2.25
15.4
5 years 2.25
Extreme 2.25
49.52
10 years 2.25
Extreme 2.25
61.69
Manager TitleAgeSince
Chief Executive Officer 61 31/07/2022
Director of Finance/CFO 54 29/02/2024
Chief Tech/Sci/R&D Officer 66 30/04/2024
Director TitleAgeSince
Chairman 74 28/03/2024
Director/Board Member 69 31/03/2020
Director/Board Member 67 28/02/2021
Date Insider Type Main position Quantity % Market Cap.
26/03/26 Free

Chief Executive Officer

542,815 0.5658%
11/03/26 Tax

Chief Financial Officer

1,781 0.0019%
02/02/26 Tax

Chief Executive Officer

16,181 0.0169%
Change 5-day change 1-year change 3-year change Capi.($)
-0.22%+17.11%+210.78%+58.85% 1.83B
+0.93%-0.63%+3.89%+14.93% 48.7B
+0.26%+2.93%+439.43%+533.80% 42.05B
-1.53%-2.25%+30.95%+7.15% 38.26B
+0.69%+2.40%+10.48%+63.05% 37.5B
+2.47%+2.63%+14.71%+48.37% 31.44B
-0.47%+1.16%+35.93%+126.09% 16.33B
+2.31%-0.49% - - 16.47B
+0.29%+1.87%+8.17%+18.60% 13.98B
-1.43%-2.63%+3.70%-36.38% 12.43B
Average +0.33%+2.39%+84.23%+92.72% 25.9B
Weighted average by Cap. +0.45%+1.05%+90.06%+120.85%

Financials

2026 *2027 *
Net sales - 61.48M 53.36M 49.96M 45.7M 86.28M 5.86B 87.41M 585M 229M 2.93B 231M 226M 9.74B
Net income -108M -94.08M -88.09M -80.58M -152M -10.33B -154M -1.03B -404M -5.16B -407M -398M -17.17B -214M -186M -174M -159M -300M -20.39B -304M -2.04B -799M -10.19B -804M -786M -33.91B
Net Debt -427M -371M -347M -317M -599M -40.68B -607M -4.06B -1.59B -20.33B -1.6B -1.57B -67.65B -511M -444M -415M -380M -717M -48.7B -727M -4.86B -1.91B -24.33B -1.92B -1.88B -80.99B
Logo COMPASS Pathways plc
Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.
Employees
156
Date Price Change Volume
06/08/26 US$13.55 -0.22% 3,423,437
05/08/26 US$13.58 +15.08% 7,682,475
04/08/26 US$11.80 +4.89% 2,369,462
03/08/26 US$11.25 -0.88% 2,775,323
31/07/26 US$11.35 -1.90% 1,986,053
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
13.55USD
Average target price
23.75USD
Spread / Average Target
+75.28%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CMPS Stock